title: The human GM2 activator protein. A substrate specific cofactor of beta-hexosaminidase A.
abstract: Ganglioside GD1a-GalNAc was isolated from Tay-Sachs brain, tritium-labeled in its sphingosine moiety, and its enzymic degradation studied in vitro and in cultured fibroblasts. When offered as micelles, GD1a-GalNAc was almost not hydrolyzed by Hex A or Hex B, while after incorporation of the ganglioside into the outer leaflet of liposomes, the terminal GalNAc residue was rapidly split off by Hex a. In striking contrast to ganglioside GM2, the major glycolipid substrate of Hex A, the enzymic hydrolysis of GD1a-GalNAc was not promoted by the GM2 activator protein, although the activator protein did bind GD1a-GalNAc to form a water-soluble complex. Pathobiochemical studies corroborate these results. After incorporation of [3H]GD1a-GalNAc into cultured skin fibroblasts from healthy subjects and from patients with different variants of GM2 gangliosidosis, its degradation was found to be strongly attenuated in mutant cells with Hex A deficiencies such as variant B (Tay-Sachs disease), variant B1 and variant 0 (Sandhoff disease), while in cells with variant AB (GM2 activator deficiency), its catabolism was blocked only at the level of GM2. In line with these metabolic studies, a normal content of GD1a-GalNAc was found in brains of patients who had succumbed to variant AB of GM2 gangliosidosis whereas in brains from variants B, B1, and 0, its concentration was considerably elevated (up to 19-fold). Together with studies on the enzymic degradation of GM2 derivatives with modifications in the ceramide portion, these results indicate that mainly steric hindrance by adjacent lipid molecules impedes the access of Hex A to membrane-bound GM2 (whose degradation therefore depends on solubilization by the GM2 activator) and in addition that the interaction between the GM2. GM2 activator complex and the enzyme must be highly specific.
authors.affiliation: Institute of Organic Chemistry and Biochemistry, University of Bonn, Federal Republic of Germany.
authors.forename: E M
authors.initials: EM
authors.lastname: Meier
authors.forename: G
authors.initials: G
authors.lastname: Schwarzmann
authors.forename: W
authors.initials: W
authors.lastname: Fürst
authors.forename: K
authors.initials: K
authors.lastname: Sandhoff
mesh_terms: D001921:Brain / Q000378:metabolism; D002478:Cells, Cultured; D004789:Enzyme Activation; D049289:G(M2) Activator Protein; D005678:G(M2) Ganglioside / Q000378:metabolism*; D005732:Gangliosides / Q000378:metabolism; D054818:Hexosaminidase A; D054819:Hexosaminidase B; D006801:Humans; D008563:Membrane Lipids / Q000378:metabolism; D008823:Micelles; D011506:Proteins / Q000378:metabolism*; D013329:Structure-Activity Relationship; D013379:Substrate Specificity; D001619:beta-N-Acetylhexosaminidases / Q000378:metabolism*
chemical_list: D049289:G(M2) Activator Protein; D005732:Gangliosides; D008563:Membrane Lipids; D008823:Micelles; D011506:Proteins; C021298:ganglioside, GD1a; D005678:G(M2) Ganglioside; D054818:Hexosaminidase A; D054819:Hexosaminidase B; D001619:beta-N-Acetylhexosaminidases